KESTRA MEDICAL TECHNOLOGIES, LTD.

Kestra Medical Technologies, Ltd. announced its 2026 Annual General Meeting of Shareholders (AGM) will be held virtually on Wednesday, September 9, 2026, at 9:00 a.m. Eastern Time. Shareholders will vote on the election of three Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm. The company's audited financial statements for the fiscal year ended April 30, 2026, will also be presented at the meeting.

Kestra Medical Technologies, Ltd. filed its 10-K, detailing its Cardiac Recovery System platform, anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD). The company, which completed its IPO in March 2025, highlights its differentiated product design, strong clinical evidence, and significant market opportunity. Kestra aims to expand its market share in the U.S. and internationally, leveraging its technology to improve patient outcomes in cardiovascular disease.

Kestra Medical Technologies reported strong financial results for the fourth quarter and fiscal year ended April 30, 2026. Q4 revenue increased 66% to $28.6 million, and FY26 revenue grew 59% to $95.1 million, with significant gross margin expansion. The company also provided positive FY27 revenue guidance of $137 million, representing 44% growth. Additionally, Kestra entered into a new five-year senior secured term loan facility of up to $200 million, replacing its prior loan agreement.

Kestra Medical Technologies, a wearable medical device company, announced a new five-year term loan facility with funds managed by Pharmakon Advisors, LP. The non-dilutive financing includes an initial $75 million tranche, which was used to retire an existing $45 million term loan, along with additional tranches totaling up to $125 million and an uncommitted $50 million for acquisitions. CEO Brian Webster stated that this financing strengthens the balance sheet, reduces the cost of capital, and provides significant financial flexibility to support growth strategies.

Kestra Medical Technologies reported strong financial results for the fourth quarter and fiscal year ended April 30, 2026. Fiscal 4Q26 revenue grew 66% to $28.6 million, and full-year 2026 revenue increased 59% to $95.1 million. The company also saw significant gross margin expansion, reaching 54.8% in Q4 and 51.4% for the full year. Kestra provided optimistic FY27 revenue guidance of $137 million, projecting 44% growth, driven by market expansion and operational achievements.

Kestra Medical Technologies, Ltd. announced it is scheduled to report its fourth quarter fiscal 2026 financial results after the market closes on Tuesday, July 14. Following the release, management will host a conference call at 4:30 p.m. Eastern Time to discuss the financial performance. A webcast of the call will be accessible via the company's investor relations website.

Kestra Medical Technologies, Ltd. (KMTS) announced its scheduled presentation at the BofA Securities 2026 Healthcare Conference. The company, a leading wearable medical device and digital healthcare firm, will present on Wednesday, May 13, at 2:20 p.m. Pacific Time. Interested parties can access the live webcast and a replay via Kestra's investor relations website.